Eli Lilly Technology Investment Impact Report

Prepared by Naftiko March 2026

Executive Summary

This report presents a comprehensive analysis of Eli Lilly’s technology investment posture, derived from Naftiko’s signal-based methodology. By examining the services deployed, tools adopted, concepts discussed, and standards followed across Eli Lilly’s technology workforce, the analysis produces a multidimensional portrait of the company’s technology commitment across foundational infrastructure, data platforms, AI capabilities, and governance frameworks.

Eli Lilly’s technology profile reveals a pharmaceutical company with exceptional depth in data analytics, governance, and security — the technology dimensions most critical for drug development and regulatory compliance. The highest scoring area is Services at 170, followed by Data at 118, Cloud at 81, Governance at 50, Operations at 44, Security at 42, and Automation at 40. Eli Lilly’s defining characteristics are its world-class data platform built on Azure Data Factory, Databricks, Snowflake, Tableau, and Power BI; its strong AI investment centered on Claude, Databricks, and Hugging Face with explicit agentic AI, prompt engineering, and vector database concepts; and its exceptionally deep governance framework covering data governance, model governance, compliance, audit, and risk management. As a global pharmaceutical leader, Eli Lilly’s technology investments directly support drug discovery, clinical trials, manufacturing, and regulatory compliance.

Layer 1: Foundational Layer

Evaluating Eli Lilly’s foundational capabilities across Artificial Intelligence, Cloud, Open-Source, Languages, and Code.

Cloud leads at 81, AI at 35, Languages at 22, Code at 12, and Open-Source at 2. The cloud and AI scores indicate substantial infrastructure investment, while the lower open-source score suggests a more proprietary technology orientation.

Artificial Intelligence — Score: 35

Claude, Databricks, and Hugging Face anchor the AI services. AI concepts are exceptionally deep: AI agents, agentic AI, agentic systems, LLMs, large language models, machine learning algorithms, neural networks, predictive modeling, prompt engineering, vector databases, model development, model deployment, and chatbot. The explicit vector databases concept alongside agentic AI and prompt engineering signals active development of RAG-powered AI applications for pharmaceutical research and operations.

Key Takeaway: Eli Lilly’s AI investment of 35 with Claude, Databricks, and explicit agentic AI/vector database concepts signals a pharmaceutical company building production AI systems for drug discovery and clinical research.

Cloud — Score: 81

AWS Lambda, Amazon Web Services, Azure, Azure Data Factory, Azure Functions, Azure Pipelines, Azure Virtual Machines, CloudFormation, Google Cloud, Microsoft Azure, Red Hat, and Red Hat Satellite with cloud concepts spanning cloud-native architecture, serverless, distributed systems, and microservices. The cloud deployment emphasis on AWS and Azure reflects pharmaceutical enterprise cloud adoption.

Relevant Waves: Large Language Models (LLMs), Generative Pre-trained Transformer (GPT), Open-Source LLMs

Open-Source — Score: 2

GitHub, Red Hat, and Red Hat Satellite with open-source contribution concepts indicate limited but present open-source engagement.

Languages — Score: 22

Bash, C#, Go, Java, Python, Perl, React, Rego, Rust, SQL, Scala, Shell, VBA, and YAML compose a comprehensive language portfolio.

Code — Score: 12

GitHub and Jenkins with CI/CD, continuous integration, software development lifecycle, and pair programming concepts.

Layer 2: Retrieval & Grounding

Evaluating Eli Lilly’s data retrieval capabilities.

Data dominates at 118 — one of the highest data scores in this analysis. Virtualization at 14 and Databases at 8 complement the data platform.

Data — Score: 118

Azure Data Factory, Databricks, Matlab, Power BI, Power Query, Snowflake, and Tableau compose the data services layer. Data concepts are extraordinarily deep with 30+ distinct concepts including data mesh, data fabric, data lineage, data lake, data governance (with framework, policies, and strategy sub-concepts), data quality standards, data visualization, and data-driven decision making. This conceptual depth is unmatched in this analysis and reflects a pharmaceutical company where data integrity and governance are not just best practices but regulatory requirements.

Key Takeaway: Eli Lilly’s Data score of 118 with data mesh, data fabric, data lineage, and data governance strategy concepts represents pharmaceutical-grade data management — the analytical foundation for drug development and clinical trial operations.

Databases — Score: 8

Elasticsearch, MySQL, PostgreSQL, and Redis with database design and vector database concepts.

Virtualization — Score: 14

Virtual machines and virtualization concepts indicate traditional infrastructure.

Specifications — Score: 5

API testing and web services concepts.

Context Engineering — Score: 0

No recorded signals.

Relevant Waves: Vector Databases, Retrieval-Augmented Generation (RAG), Prompt Engineering, Context Engineering

Layer 3: Customization & Adaptation

Evaluating Eli Lilly’s AI customization capabilities.

Data Pipelines leads at 5, Model Registry & Versioning at 2. AI customization is early-stage but building on strong foundations.

Data Pipelines — Score: 5

Azure Data Factory with data ingestion, data pipeline, ETL, and Lean Six Sigma Black Belt concepts.

Model Registry & Versioning — Score: 2

Databricks with MLOps, model deployment, and model versioning concepts.

Multimodal Infrastructure — Score: 0

Hugging Face with large language model concepts present but scoring at zero.

Domain Specialization — Score: 0

No recorded signals.

Layer 4: Efficiency & Specialization

Evaluating Eli Lilly’s operational efficiency.

Operations leads at 44, Automation at 40, Platform at 18.

Automation — Score: 40

Ansible Automation Platform, Power Apps, and Power Platform with automation, workflow automation, test automation, process automation, and deployment automation concepts. The depth of automation concepts indicates enterprise-wide automation adoption.

Containers — Score: 8

Container orchestration, containerization, and containers concepts indicate growing container adoption.

Platform — Score: 18

Amazon Web Services, Microsoft Azure, Power Platform, Salesforce, and Workday with extensive platform concepts including platform engineering, platform development, cloud computing platforms, and data platforms.

Operations — Score: 44

Datadog and New Relic with cloud operations, incident management, incident response, operations research, and service management concepts.

Relevant Waves: Small Language Models (SLMs), Model Routing / Orchestration, Reasoning Models

Layer 5: Productivity

Evaluating Eli Lilly’s productivity capabilities.

Services dominates at 170.

Software As A Service (SaaS) — Score: 0

Box, Concur, Salesforce, and Workday captured within Services.

Code — Score: 12

GitHub and Jenkins with CI/CD and software development practices.

Services — Score: 170

Over 160 distinct services spanning cloud (AWS, Azure, Google Cloud), data (Databricks, Snowflake, Tableau, Power BI), collaboration (Confluence, Jira, Microsoft Office), security (Cloudflare, Checkmarx), AI (Claude, Hugging Face), testing (Selenium, Playwright, Cucumber, JMeter, Appium, Jest), and pharmaceutical-relevant platforms. The testing tool depth is notable — Selenium, Playwright, Cucumber, JMeter, Appium, and Jest — reflecting quality assurance requirements in pharmaceutical software development.

Relevant Waves: Coding Assistants, Copilots

Layer 6: Integration & Interoperability

Evaluating Eli Lilly’s integration capabilities.

Integrations leads at 25, Apache and CNCF both at 22, Patterns at 14, API at 13.

API — Score: 13

Kong, Mulesoft, and Postman with API, API testing, API-first, OpenAPI, REST, and web services concepts.

Integrations — Score: 25

Azure Data Factory, Mulesoft, Panorama, and Workato with integration patterns, middleware, and system integration concepts.

Event-Driven — Score: 8

Event-driven architecture, event-driven systems, and real-time streaming concepts.

Patterns — Score: 14

Design patterns, microservices, and microservices architecture concepts.

Specifications — Score: 5

API testing and web services concepts.

Apache — Score: 22

Notable Apache investment with significant tool breadth.

CNCF — Score: 22

Argo, CNCF, Capsule, Cloud Custodian, Cortex, Dex, Distribution, Fluid, Flux, Harbor, Helm, Jaeger, Kubernetes, Lima, ORAS, OpenTelemetry, Porter, Prometheus, SPIRE, Score, Stacker, and werf — an extraordinarily deep CNCF adoption profile with 22 distinct tools. This is one of the deepest CNCF investments in this analysis.

Relevant Waves: MCP (Model Context Protocol), Agents, Skills

Key Takeaway: Eli Lilly’s CNCF score of 22 with 22 distinct cloud-native tools signals a pharmaceutical company with cutting-edge infrastructure engineering capabilities.

Layer 7: Statefulness

Evaluating Eli Lilly’s statefulness capabilities.

Data leads at 118, Governance at 50, Security at 42, Observability at 22.

Observability — Score: 22

Datadog, Grafana, New Relic, and Splunk with alerting, data observability, logging, monitoring, observability platforms, performance monitoring, and security monitoring concepts.

Governance — Score: 50

This is Eli Lilly’s standout governance signal. Concepts include audit, audit processes, audit trails, compliance (with framework, management, oversight, policies, and systems sub-concepts), data governance (with framework, frameworks, policies, and strategy), governance (with framework and frameworks), internal audit, internal controls, model governance, policy as code, project governance, regulatory compliance, regulatory filings, regulatory reporting, risk assessment (with assessments), risk management (with plan, systems, tools), and third-party risk management.

This governance depth is exceptional and directly reflects pharmaceutical industry requirements where regulatory compliance, clinical trial governance, and data integrity are existential business concerns.

Key Takeaway: Eli Lilly’s Governance score of 50 with model governance, policy as code, and 30+ governance concepts represents pharmaceutical-grade technology governance.

Security — Score: 42

Cloudflare with 30+ security concepts spanning authentication, authorization, cloud security, cybersecurity, data security, encryption, endpoint security, incident response, network security, platform security, security architecture, security engineering, threat intelligence, and vulnerability scanning.

Data — Score: 118

Mirrors the Retrieval & Grounding assessment.

Relevant Waves: Memory Systems

Layer 8: Measurement & Accountability

Evaluating Eli Lilly’s measurement capabilities.

Observability leads at 22, Testing & Quality at 7.

Testing & Quality — Score: 7

30+ testing and quality concepts including acceptance testing, accessibility testing, automated testing, data quality, functional testing, infrastructure testing, integration testing, performance testing, quality assurance, quality management, security testing, software testing, and unit testing. This breadth reflects pharmaceutical validation requirements.

Observability — Score: 22

Mirrors the Statefulness layer.

Developer Experience — Score: 5

GitHub as the primary developer platform.

ROI & Business Metrics — Score: 3

Power BI and Tableau with business analytics, cost optimization, financial modeling, and time series forecasting concepts.

Relevant Waves: Evaluation & Benchmarking

Layer 9: Governance & Risk

Evaluating Eli Lilly’s governance and risk capabilities.

Governance leads at 50, Security at 42. This is the strongest governance layer in this analysis.

Regulatory Posture — Score: 4

Compliance framework, compliance management, regulatory compliance, and regulatory reporting concepts.

AI Review & Approval — Score: 5

Model development concepts for AI governance.

Security — Score: 42

Mirrors the Statefulness layer.

Governance — Score: 50

Mirrors the Statefulness layer with pharmaceutical-grade governance depth.

Privacy & Data Rights — Score: 3

Data privacy, data protection, and privacy by design concepts — critical for pharmaceutical patient data handling.

Relevant Waves: Governance & Compliance

Layer 10: Economics & Sustainability

Evaluating Eli Lilly’s economic sustainability.

Partnerships & Ecosystem leads at 5.

AI FinOps — Score: 1

AWS and Azure with cost optimization concepts.

Provider Strategy — Score: 0

Multi-vendor dependencies across Microsoft, Amazon, Oracle, SAP, and Salesforce.

Partnerships & Ecosystem — Score: 5

LinkedIn, Microsoft, Oracle, SAP, and Salesforce ecosystems.

Talent & Organizational Design — Score: 2

LinkedIn and Workday with learning and model training concepts.

Data Centers — Score: 0

No recorded signals.

Layer 11: Storytelling & Entertainment & Theater

Evaluating Eli Lilly’s strategic alignment capabilities.

Alignment leads at 20, Standardization at 15.

Alignment — Score: 20

Architecture, architecture design, architecture strategy, cloud architecture, data architecture, digital transformation, event-driven architecture, lakehouse architecture, microservices architecture, security architecture, serverless architectures, and system architecture concepts. The lakehouse architecture concept alongside data architecture and cloud-native architecture signals advanced data platform thinking.

Standardization — Score: 15

Data standardization, standard operating procedures, and standardization concepts — directly relevant to pharmaceutical manufacturing and regulatory compliance.

Mergers & Acquisitions — Score: 10

Active M&A signals.

Experimentation & Prototyping — Score: 0

No recorded signals.

Relevant Waves: Moltbook, Gastown, Ralph Wiggum, OpenClaw / Clawdbot, Artificial General Intelligence (AGI)

Strategic Assessment

Eli Lilly’s technology investment profile reveals a pharmaceutical company with world-class data and governance capabilities. The company’s highest signals — Services (170), Data (118), Cloud (81), Governance (50), Operations (44), Security (42), Automation (40) — form a pattern uniquely suited to pharmaceutical operations where data integrity, regulatory compliance, and operational precision are non-negotiable. The Data score of 118 with data mesh, data fabric, and data lineage concepts, combined with the Governance score of 50 with model governance and policy as code, places Eli Lilly at the forefront of regulated industry technology management. The AI investment (35) centered on Claude, Databricks, and agentic AI concepts signals an active push to apply AI to drug discovery and clinical research.

Strengths

Eli Lilly’s strengths reflect the technology capabilities of a world-leading pharmaceutical enterprise.

Area Evidence
World-Class Data Platform Data score of 118 with Snowflake, Databricks, Tableau, and data mesh/fabric/lineage concepts
Pharmaceutical Governance Governance score of 50 with model governance, policy as code, and 30+ governance concepts
Enterprise Cloud Cloud score of 81 with AWS, Azure, and cloud-native architecture
Security Depth Security score of 42 with 30+ security concepts and comprehensive controls
AI for Pharma AI score of 35 with Claude, agentic AI, prompt engineering, and vector databases
CNCF Infrastructure CNCF score of 22 with 22 distinct cloud-native tools
Testing & Validation 30+ testing concepts reflecting pharmaceutical quality requirements

The convergence of data platform, governance, and AI capabilities is the most strategically significant pattern. Eli Lilly’s ability to manage pharmaceutical data with rigorous governance while applying advanced AI techniques creates a competitive advantage in drug discovery and clinical trial optimization. The data mesh and lakehouse architecture concepts suggest the company is building a modern data platform designed specifically for pharmaceutical research workflows.

Growth Opportunities

Area Current State Opportunity
Context Engineering Score: 0 Building RAG systems that leverage clinical trial data and medical literature for AI-assisted drug discovery
Domain Specialization Score: 0 Developing pharmaceutical-specific AI models for molecular design, clinical trial optimization, and pharmacovigilance
Open-Source Engagement Score: 2 Expanding open-source participation to attract top AI and data engineering talent
Developer Experience Score: 5 Investing in developer platforms to accelerate internal innovation velocity

The highest-leverage opportunity is Context Engineering for Drug Discovery. Eli Lilly’s massive pharmaceutical data assets (clinical trials, molecular data, regulatory submissions) combined with its existing Claude/Databricks AI infrastructure and rigorous data governance create the ideal foundation for RAG-powered AI systems that could accelerate drug discovery timelines. The vector database concepts already present in the AI layer suggest this direction is being explored.

Wave Alignment

The most consequential wave alignment for Eli Lilly is RAG combined with Agents and Governance & Compliance. AI agents that can retrieve and reason over clinical and regulatory data while operating within Eli Lilly’s governance framework would transform pharmaceutical research and regulatory operations. The existing data governance infrastructure, model governance concepts, and policy as code approach provide the trust and compliance layer these AI agents would require.

Methodology

This impact report is generated from Naftiko’s signal-based investment analysis framework. Scores are derived from the density and diversity of technology signals detected across four dimensions:

Each signal is scored and aggregated within strategic layers that map the full technology stack from foundational infrastructure through productivity and governance. Higher scores indicate greater investment depth and breadth within a given dimension.

This report is based on signal data available as of March 2026. Investment signals are dynamic and may change as Eli Lilly’s technology strategy evolves. For questions about methodology or to request an updated analysis, contact Naftiko.